- Home
- JANX vs TILE Comparison
JANX vs TILE Comparison
Compare JANX & TILE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- TILE
- Stock Information
- Founded
- JANX 2017
- TILE 1973
- Country
- JANX United States
- TILE United States
- Employees
- JANX N/A
- TILE N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- TILE Home Furnishings
- Sector
- JANX Health Care
- TILE Consumer Discretionary
- Exchange
- JANX Nasdaq
- TILE Nasdaq
- Market Cap
- JANX 1.4B
- TILE 1.4B
- IPO Year
- JANX 2021
- TILE N/A
- Fundamental
- Price
- JANX $24.87
- TILE $26.36
- Analyst Decision
- JANX Strong Buy
- TILE Buy
- Analyst Count
- JANX 8
- TILE 1
- Target Price
- JANX $90.63
- TILE $32.00
- AVG Volume (30 Days)
- JANX 892.8K
- TILE 404.0K
- Earning Date
- JANX 08-07-2025
- TILE 08-01-2025
- Dividend Yield
- JANX N/A
- TILE 0.15%
- EPS Growth
- JANX N/A
- TILE 43.35
- EPS
- JANX N/A
- TILE 1.62
- Revenue
- JANX $439,000.00
- TILE $1,352,215,000.00
- Revenue This Year
- JANX N/A
- TILE $5.19
- Revenue Next Year
- JANX $1,470.83
- TILE $4.91
- P/E Ratio
- JANX N/A
- TILE $16.51
- Revenue Growth
- JANX N/A
- TILE 6.26
- 52 Week Low
- JANX $21.97
- TILE $16.53
- 52 Week High
- JANX $71.71
- TILE $27.34
- Technical
- Relative Strength Index (RSI)
- JANX 51.13
- TILE 69.66
- Support Level
- JANX $23.96
- TILE $24.58
- Resistance Level
- JANX $25.93
- TILE $27.25
- Average True Range (ATR)
- JANX 1.55
- TILE 0.93
- MACD
- JANX 0.06
- TILE 0.32
- Stochastic Oscillator
- JANX 61.91
- TILE 87.83
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.